Capecitabine or S-1

Phase 2

CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Capecitabine or S-1 is one of 11 therapeutic programs targeting Biliary Tract Cancer (BTC). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Biliary Tract Cancer (BTC)Recruiting

Extrahepatic CholangiocarcinomaRecruiting

Biliary Tract Cancer (BTC)Phase 2

Recruiting

Extrahepatic CholangiocarcinomaPhase 2

Recruiting

Competition

Competitive Landscape

10 competitors in Biliary Tract Cancer (BTC)

#DrugCompanyPhaseTrials

Zaniducla

Jazz Pharmaceuticals

Phase 3

1 2

Lytgobi

Taiho Oncology, Inc.

Phase 3

1 3

Tibsovo

SServier

Phase 3

1 4

Gemzar

Johnson & Johnson

Phase 2

2 5

Rasonque

Revolution Medicines

Phase 2

1 6

PD-1 Inhibitors

BBioNTech US Inc.

Phase 2

1 7

Iparomlimab and Tuvonralimab

Qilu Pharmaceutical Co., Ltd.

Phase 2

1 8

Capecitabine or S-1

CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase 2

1 9

PD-1 and Chemotherapy

TTongji University

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Recruiting

Biliary Tract Cancer (BTC)

NCT07893392

Q2 2029

Phase 2Recruiting

Extrahepatic Cholangiocarcinoma

NCT07636824

Clinical

Trials by Indication[1]

Biliary Tract Cancer (BTC)1 trial

Phase II Study of Primary Tumor Resection and Selective Lymph Node Dissection Followed by Postoperative Radiotherapy for Biliary Tract Cancer With Lymph Node Metastases

Recruiting·CCancer Institute and Hospital, Chinese Academy of Medical Sciences·Phase 2·NCT07893392·73 enrolled

Extrahepatic Cholangiocarcinoma1 trial

Efficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study

Recruiting·CCancer Institute and Hospital, Chinese Academy of Medical Sciences·Phase 2·NCT07636824·92 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Capecitabine or S-1. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Capecitabine or S-1. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Cancer Institute and Hospital, Chinese Academy of Medical Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 2[1]
Company: CCancer Institute and Hospital, Chinese Academy of Medical Sciences

Capecitabine or S-1

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q4 2028

Q2 2029

Trials by Indication[1]

Biliary Tract Cancer (BTC)1 trial

Extrahepatic Cholangiocarcinoma1 trial

References

Drug Info

Quick Facts

Related News